Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab therapy

• Tolerate the standard infusion rituximab with ≤ grade 2 hypersensitivity reaction

• Consent to participate in the rapid infusion study

• Age ≥ 18 years ≤ 80 years

Exclusion Criteria:

• Tolerate the standard infusion rituximab with ≥ grade 3 hypersensitivity reaction

• Neurocognitive impairment (i.e. dementia, Alzheimers, et al)